FIELD: biotechnology.
SUBSTANCE: proposed is an anti-cancer agent containing a bispecific antibody as an active ingredient. Stated bispecific antibody contains variable areas of the antibody connecting with glypican 3 and CD3 and contains identical light strands. Also proposed is a pharmaceutical composition containing a bispecific antibody as an active ingredient. Composition is intended for co-use with another anti-cancer medicinal product. Invention also relates to cytotoxicity induction, cellular proliferation inhibition and immune response activation agents containing such composition. Bispecific antibodies constitute new and highly safe molecules characterized by high processability, strong antitumor activity and very high pharmacokinetic properties.
EFFECT: invention may be used in treatment of various types of cancer.
17 cl, 47 dwg, 21 tbl, 15 ex
Title | Year | Author | Number |
---|---|---|---|
CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2812875C1 |
CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
ANTIBODY TO GLYPICAN 3 | 2011 |
|
RU2611751C2 |
GLYPICAN-3 ANTIBODY | 2005 |
|
RU2427588C2 |
CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
MEDICATION FOR TREATMENT OF LIVER CANCER | 2009 |
|
RU2523897C2 |
ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
THERAPEUTIC ANTIBODIES AND THEIR APPLICATION | 2016 |
|
RU2722381C2 |
MODIFIED EXOTOXIN A PSEUDOMONADES | 2014 |
|
RU2687143C2 |
ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
Authors
Dates
2021-04-20—Published
2017-02-24—Filed